Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20589559 | 0.94 | EPHX2 (1.00) | EPHX2PPARG | |
| SCHEMBL20942713 | 0.92 | EPHX2 (0.84) | EPHX2PPARG | |
| SCHEMBL14126205 | 0.90 | EPHX2 (0.88) | EPHX2PPARG | |
| SCHEMBL14126269 | 0.90 | EPHX2 (0.88) | EPHX2PPARG | |
| SCHEMBL20587730 | 0.89 | EPHX2 (1.00) | EPHX2PPARG | |
| SCHEMBL28663274 | 0.87 | EPHX2 (0.82) | EPHX2PPARG | |
| SCHEMBL20588158 | 0.87 | EPHX2 (1.00) | EPHX2PPARG | |
| SCHEMBL20587786 | 0.86 | EPHX2 (1.00) | EPHX2PPARG | |
| SCHEMBL20919988 | 0.85 | EPHX2 (0.84) | EPHX2PPARG | |
| SCHEMBL29557598 | 0.81 | EPHX2 (1.00) | EPHX2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210161881-A1 | METHODS OF INHIBITING FORMATION OF ALPHA SYNUCLEIN AGGREGATES | CHIBA UNIVERSITY (JP) | 2021-06-03 | — | — | US | claimed |
| US-20210145891-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-20 | — | — | US | claimed |
| WO-2019156991-A1 | METHODS OF INHIBITING FORMATION OF ALPHA SYNUCLEIN AGGREGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-15 | — | — | WO | claimed |
| WO-2018231702-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-12-20 | — | — | WO | claimed |
| US-12251379-B2 | Methods of inhibiting formation of alpha synuclein aggregates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-18 | — | — | US | disclosed |
| US-11723929-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | disclosed |
| US-11572347-B2 | Orally available sEH/PDE4 dual inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-07 | — | — | US | disclosed |
| US-11572347-B2 | Orally available sEH/PDE4 dual inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210395202-A1 | ORALLY AVAILABLE SEH/PDE4 DUAL INHIBITORS | GOETHE-UNIVERSITY FRANKFURT (DE) | 2021-12-23 | — | — | US | disclosed |
| US-20210395202-A1 | ORALLY AVAILABLE SEH/PDE4 DUAL INHIBITORS | GOETHE-UNIVERSITY FRANKFURT (DE) | 2021-12-23 | — | — | US | disclosed |
| US-20210161881-A1 | METHODS OF INHIBITING FORMATION OF ALPHA SYNUCLEIN AGGREGATES | CHIBA UNIVERSITY (JP) | 2021-06-03 | — | — | US | disclosed |
| US-20210145891-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-05-20 | — | — | US | disclosed |
| WO-2019156991-A1 | METHODS OF INHIBITING FORMATION OF ALPHA SYNUCLEIN AGGREGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019079609-A1 | ORALLY AVAILABLE SEH/PDE4 DUAL INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019079609-A1 | ORALLY AVAILABLE SEH/PDE4 DUAL INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-04-25 | — | — | WO | disclosed |
| WO-2018231702-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572347-B2 | Orally available sEH/PDE4 dual inhibitors | EPHX1, PDE4A, EPHX2 | EPHX2 3/4885PPARG 1178/4885 |
| US-11723929-B2 | Methods of improving cell-based therapy | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885PPARG 1194/4885 |
| US-20210161881-A1 | METHODS OF INHIBITING FORMATION OF ALPHA SYNUCLEIN AGGREGATES | SNCA, PARK7, PYGB | EPHX2 3967/4885PPARG 3309/4885 |
| US-12251379-B2 | Methods of inhibiting formation of alpha synuclein aggregates | SNCA, PARK7, PYGB | EPHX2 3967/4885PPARG 3309/4885 |
| US-20210145891-A1 | METHODS OF IMPROVING CELL-BASED THERAPY | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885PPARG 1194/4885 |
| US-20210395202-A1 | ORALLY AVAILABLE SEH/PDE4 DUAL INHIBITORS | EPHX1, PDE4A, EPHX2 | EPHX2 3/4885PPARG 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.